Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 20/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077331 | 0.91 | SLC6A4 (0.59) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18769587 | 0.91 | SLC6A4 (0.59) | SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL18742610 | 0.90 | SLC6A4 (0.58) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL16649648 | 0.86 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL12497571 | 0.83 | OPRM1 (0.59) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL24267986 | 0.81 | SLC6A4 (0.37) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL18742767 | 0.81 | SLC6A3 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL23231386 | 0.81 | SLC6A3 (0.37) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL13229764 | 0.81 | SLC6A3 (0.56) | SLC6A4SLC6A3SLC6A2 | |
| Hydrochloric Acid SCHEMBL18742759 | 0.79 | SLC6A3 (0.54) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174611-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-4288414-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| CN-116806217-A | Substituted cyclic modulators of protein phosphatase 2A (PP 2A) and methods of use thereof | 拉帕塔疗法公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-110997661-B | Cyclopropyl ureaplatin 2 receptor and formyl peptide 1 receptor agonists | 百时美施贵宝公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022167867-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| WO-2022167867-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2022-08-11 | — | — | WO | disclosed |
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3634958-B1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021071843-A1 | MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS | Pipeline Therapeutics, Inc. (US) | 2021-04-15 | — | — | WO | disclosed |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-06-25 | — | — | US | disclosed |
| WO-2018227067-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-13 | — | — | WO | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2010-07-01 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | DEVGEN NV (BE) | 2009-05-07 | — | — | US | disclosed |
| EP-2048142-A2 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | Eisai R&D Management Co., Ltd. (JP) | 2009-04-15 | — | — | EP | disclosed |
| EP-1382603-B1 | NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-07-23 | — | — | EP | disclosed |
| WO-2007006546-A1 | AMIDE DERIVATIVES AS KINASE INHIBITORS | DEVGEN N.V. (BE) | 2007-01-18 | — | — | WO | disclosed |
| US-7074801-B1 | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof | EISAI CO., LTD. (JP) | 2006-07-11 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180490-B2 | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists | FPR1, FPR2, FPR3 | SLC6A4 4510/4885SLC6A3 4747/4885SLC6A2 4291/4885 |
| US-20100168102-A9 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | SLC6A4 2702/4885SLC6A3 2118/4885SLC6A2 1835/4885 |
| US-20200199113-A1 | CYCLOPROPYL UREA FORMYL PEPTIDE 2 RECEPTOR AND FORMYL PEPTIDE 1 RECEPTOR AGONISTS | FPR1, FPR2, FPR3 | SLC6A4 4510/4885SLC6A3 4747/4885SLC6A2 4291/4885 |
| US-20090118283-A1 | Amide Derivatives as Kinase Inhibitors | MAP3K1, CDK1, CDK2 | SLC6A4 2702/4885SLC6A3 2118/4885SLC6A2 1835/4885 |
| US-20240174611-A1 | SUBSTITUTED CYCLIC MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPP2CA, PPP3CA, PPP4C | SLC6A4 3783/4885SLC6A3 4307/4885SLC6A2 3526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.